Standing out in the field of IgY Immunotechnology

  • Home
    Home A full collection of all the Research Archive entries.
  • Years
    Years Sort entries by year.
  • Tags
    Tags Displays a list of tags that have been used in the blog.
  • Archives
    Archives Contains a list of research entries that were created previously.

Therapeutic potential of combined anti-IL-1β IgY and anti-TNF-α IgY in guinea pigs with allergic rhinitis induced by ovalbumin.

Posted by on in 2014
  • Font size: Larger Smaller
  • Hits: 3218
  • Print
  • Guo-Zhu H1Xi-Ling Z2Zhu W3Li-Hua W1Dan H1Xiao-Mu W1Wen-Yun Z1Wei-Xu H4. 2014. Int Immunopharmacol.  pii: S1567-5769(14)00470-6. doi: 10.1016/j.intimp.2014.12.002. [Epub ahead of print]
  • 1Institute of Clinical Medical Sciences, Jiangxi Province People's Hospital, Nanchang 330006, Jiangxi, China.
  • 2College of Agriculture, Anshun University, Anshun 561000, Guizhou, China.
  • 3Department of Hematology, Jiangxi Academy of Medical Science, Nanchang 330006, Jiangxi, China. 
  • 4Department of Radiation Oncology, Zhongshan Hospital Fudan Universitay, Shanghai 200032, China. Electronic address:


We have previously demonstrated that anti-IL-1β immunoglobulin yolk(IgY) inhibits pathological responses in allergic asthma guinea pigs induced by ovalbumin(OVA). This study aims to determine whether the combined blockade of IL-1β and TNF-α can more effectively inhibit allergic inflammation in allergic rhinitis(AR) guinea pigs induced by OVA. Healthy guinea pigs treated with saline were used as the healthy control. The AR guinea pigs induced by OVA were randomly divided into (1) the AR model group containing negative control animals treated with intranasal saline; (2) the 0.1% non-specific IgY treatment group treated with non-specific IgY; (3) the 0.1% anti-TNF-α IgY treatment group treated with 0.1% anti-TNF-α IgY; (4) the 0.1% anti-IL-1β IgY treatment group treated with 0.1% anti-IL-1β IgY; (5) the 0.1% combined anti-IL-1β IgY and anti-TNF-α IgY treatment group treated with 0.1% combined anti-IL-1β IgY and anti-TNF-α IgY; and (6) the fluticasone propionate treatment group treated with fluticasone propionate. Cytokines were measured using an enzyme-linked immunosorbent assay. The results showed that IL-1β, IL-5, IL-9, IL-13, IL-18, IL-22, IL-33, TNF-α, TGF-β1 and OVA-specific IgE levels in the peripheral blood (PB) and nasal lavage fluid (NLF) significantly decreased at 2h, 4h or 8h in the 0.1% combined anti-IL-1β IgY and anti-TNF-α IgY treatment group compared to the AR model group and the 0.1% non-specific IgY treatment group (P<0.05). The data suggest that blockade of IL-1β and TNF-α by intranasal instillation of combined anti-IL-1β IgY and anti-TNF-α IgY could be a potential alternative strategy for preventing and treating allergic rhinitis.

Copyright © 2014. Published by Elsevier B.V.


Allergic rhinitis; Cytokines; Guinea pigs; Immunoglobulin yolk; Interleukin-1beta; OVA; Tumor necrosis factor-alpha

[PubMed - as supplied by publisher]
Last modified on